Clinical benefit without sweat chloride response after ETI therapy in an adult with cystic fibrosis bearing the L467F;F508del complex CFTR allele: a case report and the role of AI-assisted chest CT in longitudinal monitoring. (PubMed, Front Med (Lausanne)) - Sep 13, 2026 - "Elexacaftor/tezacaftor/ivacaftor (ETI) is the standard of care for most people with cystic fibrosis (CF) who carry at least one F508del allele. An exploratory in vitro rescue study with vanzacaftor/tezacaftor supports the evaluation of emerging CFTR modulators. It suggests that similar studies should be conducted in other cases involving complex CFTR alleles."
Journal • Bronchiectasis • Cystic Fibrosis • Genetic Disorders • Immunology • Pulmonary Disease • Respiratory Diseases
|
|
Aurélie Hatton; Daan Caudri; Eva Furstova; Hana Hrdinová; Isabelle Sermet-Gaudelus; Jan Baxa; Josef Sýkora; Libor Fila; Malgorzata Libik; Marcela Kreslová; Milan Macek; Nela Stastna; Punitkumar Makani; Radka Bittenglová; Václav Koucký
|